Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Prime Minister plans a whistle-stop charm offensive with EU leaders this week.
Thriller writer Anthony Horowitz is at the helm of the latest Bond book, which is based on an unfilmed Ian Fleming TV script.
Actress who plays iconic Daenerys Targaryen admitted she didn't want to become typecast for nudity.